新辅助化疗对乳腺癌ki67、cox-2、p53表达的影响及其临床意义  

Effect of neoadjuvant chemotherapy on ki67,cox-2,p53 expression in breast cancer and its significance

作　　者：林其声[1,2] 施雄文[1,2] 徐书楷[1,2] 蒋新宇[1,2] 

机构地区：[1]福建省三明市第二医院肿瘤科 [2]福建医科大学临床教学专业基地,福建永安366000

出　　处：《中国当代医药》2009年第24期13-14,共2页China Modern Medicine

摘　　要：目的:探讨新辅助化疗对ki67、cox-2、p53表达的影响,分析表达变化与临床疗效的关系。方法:用免疫组化Envision法分别检测61例可手术的乳腺癌患者新辅助化疗前后ki67、cox-2、p53表达情况。结果:①术前新辅助化疗后,ki67、cox-2的表达明显下降,p53的表达变化无显著差异性改变。②ki67的高表达的患者新辅助化疗效果明显好于低表达,cox-2阴性的化疗效果优于cox-2阳性,p53阴性的化疗效果亦好于p53阳性的。结论:化疗前检测乳腺癌的ki67、cox-2、p53,可以指导新辅助化疗,并且是疗效判断的分子生物学指标。Objective： To study the effect of neoadjuvant chemotherapy on the expressions of ki670,cox-2,p53 in breast cancer tissues, and analyze the relationship between expression changes and efficency of neoadjuvant chemotherapy. Methods： The expression of the ki67,cox-2 and p53 in 61 patients with breast cancer were examined by immunohistochemical as say before and after neoadjuvant chelnotherapy. Results： ①After neoadjuvant chemotherapy, the expression ki67 ,cox-2 decreased significantly, but p53 showed no significant changes. ②Patients with high expression of ki67 were more likely respond to neoadjuvant chemotherapy. The effect of neoadjuvant chemotherapy had a significantly negative correlation with p53 and cox-2 expression. Conclusion： The results indicate that the expressions of ki67,cox-2,p53 are strong prognostic molecular markers and can be a guide for neoadjuvant chemotherapy. It is predication of prognosis for patients with breast cancer.

关 键 词：乳腺癌 新辅助化疗 KI67 COX-2 P53 

分 类 号：R737.9[医药卫生—肿瘤]